This post was just published on ZYX Buy Change Alert. A quick denial of a potential deal is not typical, as has happened in the case of FLXN.  One hypothetical explanation is that  the deal is potentially in the works but a quick run-up in the stock makes the deal difficult.  Hypothetically, this could be the reason for a quick denial. Fortunately we were able to be nimble. Subscribers who were able to be nimble made some profits.  Subscribers who were not able to be nimble, did not lose any money. The Plan If the historical pattern holds, the stock is likely

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage. FLXN is a biopharma. There are reports of a potential buyout buy SNY.  The stock is jumping as we are writing.  This is suitable only for super aggressive investors as the risk of loss